Dr. Paul Averback reports

NYMOX ANNOUNCES APPOINTMENT OF PATRICK DOODY AS VICE PRESIDENT AND MEMBER OF THE BOARD OF DIRECTORS OF NYMOX

Nymox Pharmaceutical Corp. has appointed Patrick Doody as Nymox vice-president, general counsel and member of Nymox's board of directors.

Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the intellectual property group, and currently is senior counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in postgrant proceedings, patent infringement litigation, patent prosecution, licensing, opinions and counselling. Mr. Doody has represented Nymox and its predecessor company in intellectual property matters for over 30 years, securing hundreds of issued patents for Nymox throughout the world. Mr. Doody is a former patent examiner, former in-house counsel for Union Carbide Corp., former partner at Tier 1, AMLAW 100 firms and also is an adjunct professor of patent law at the George Washington University School of Law. Mr. Doody obtained his BS degree in chemical engineering from Virginia Tech, and his law degree from the Scalia School of Law (formerly George Mason School of Law), has served in a number of leadership positions in various intellectual property associations, is ranked Band 2 by Chambers for intellectual property and AV ranked by Martindale Hubbell. Much of Mr. Doody's legal career has involved counselling biotechnology, pharmaceutical and chemical companies on all aspects of intellectual property law.

Dr. Paul Averback, chief executive officer and chairman of Nymox, said: "Patrick brings with him decades of experience with industry and in legal intellectual property practice. He is highly sophisticated and has a sterling reputation, and has worked in some of the best law practices in the world, including for many years as partner at Pillsbury Winthrop. Patrick has worked on many of the company's important files for a span of over 30 years and has our confidence that he will bring his integrity and legal expertise to our management team and to the board of directors of the company. In addition to legal matters, Pat is extremely well versed in our technologies and understands the detailed biochemical and biomedical aspects of our work, which is a potent legal plus scientific combination that the company is pleased to add to management and to the board. He has valuable work experience from the real world of industry which is a major positive for this position."

Nymox is in the process of submitting applications for the approval to market the company's first-in-class drug Nymozarfex to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle-aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects, including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective but it is not without risks, the discomforts of surgery and BPH surgery has side effects such as permanent retrograde ejaculation for many patients.

About Nymozarfex (fexapotide)

Nymozarfex is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving over all more than 1,750 patients with over 1,600 injections administered, including over 1,200 fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.

We seek Safe Harbor.